{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T18:09:10Z","timestamp":1792346950156,"version":"4.4.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,10]],"date-time":"2023-06-10T00:00:00Z","timestamp":1686355200000},"content-version":"am","delay-in-days":344,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Child and Adolescent Psychiatric Clinics of North America"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.chc.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T08:02:58Z","timestamp":1652256178000},"page":"417-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Nonstimulant Treatments for ADHD"],"prefix":"10.1016","volume":"31","author":[{"given":"Jeffrey H.","family":"Newcorn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Krone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf W.","family":"Dittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.chc.2022.03.005_bib1","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1974.01760120049008","article-title":"Imipramine and methylphenidate treatments of hyperactive boys. A double-blind comparison","volume":"30","author":"Rapoport","year":"1974","journal-title":"Arch Gen Psychiatry"},{"issue":"Suppl 1","key":"10.1016\/j.chc.2022.03.005_bib2","first-page":"I102","article-title":"Non-stimulant medications in the treatment of ADHD","volume":"13","author":"Banaschewski","year":"2004","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib3","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00004583-200102000-00011","article-title":"Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment","volume":"40","author":"Swanson","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2022.03.005_bib4","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s40263-021-00848-3","article-title":"A\u00a0practical, evidence-informed approach to managing stimulant-refractory attention deficit hyperactivity disorder (ADHD)","volume":"35","author":"Cortese","year":"2021","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib5","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jaac.2019.06.012","article-title":"Systematic review: nonmedical use of prescription stimulants: risk factors, outcomes, and risk reduction strategies","volume":"59","author":"Faraone","year":"2020","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"10222","key":"10.1016\/j.chc.2022.03.005_bib6","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0140-6736(19)33004-1","article-title":"Attention-deficit hyperactivity disorder","volume":"395","author":"Posner","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.chc.2022.03.005_bib7","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.biopsych.2004.11.006","article-title":"Imaging the effects of methylphenidate on brain dopamine: new model on its therapeutic actions for attention-deficit\/hyperactivity disorder","volume":"57","author":"Volkow","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2022.03.005_bib8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.biopsych.2004.08.019","article-title":"Neurobiology of executive functions: catecholamine influences on prefrontal cortical functions","volume":"57","author":"Arnsten","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2022.03.005_bib9","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0893-133X(02)00346-9","article-title":"Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit\/hyperactivity disorder","volume":"27","author":"Bymaster","year":"2002","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.chc.2022.03.005_bib10","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1097\/CHI.0b013e31819c55b2","article-title":"Clinical responses to atomoxetine in attention-deficit\/hyperactivity disorder: the Integrated Data Exploratory Analysis (IDEA) study","volume":"48","author":"Newcorn","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2022.03.005_bib11","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40263-016-0346-3","article-title":"Relationships between functional outcomes and symptomatic improvement in atomoxetine-treated adult patients with attention-deficit\/hyperactivity disorder: post hoc analysis of an integrated database","volume":"30","author":"De Bruyckere","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib12","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1097\/01.chi.0000246056.83791.b6","article-title":"CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD","volume":"46","author":"Michelson","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"13","key":"10.1016\/j.chc.2022.03.005_bib13","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.2217\/PGS.15.93","article-title":"Atomoxetine pharmacogenetics: associations with pharmacokinetics, treatment response and tolerability","volume":"16","author":"Brown","year":"2015","journal-title":"Pharmacogenomics"},{"issue":"Suppl 12","key":"10.1016\/j.chc.2022.03.005_bib14","first-page":"50","article-title":"Safety profile of atomoxetine in the treatment of children and adolescents with ADHD","volume":"63","author":"Wernicke","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2022.03.005_bib15","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s40263-016-0349-0","article-title":"The safety of atomoxetine for the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a comprehensive review of over a decade of research","volume":"30","author":"Reed","year":"2016","journal-title":"CNS Drugs"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib16","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1097\/chi.0b013e31815d88b2","article-title":"Meta-analysis of suicide-related behavior events in patients treated with atomoxetine","volume":"47","author":"Bangs","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"8","key":"10.1016\/j.chc.2022.03.005_bib17","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1001\/jama.1982.03320330064029","article-title":"Stimulant medications precipitate Tourette's syndrome","volume":"247","author":"Lowe","year":"1982","journal-title":"Jama"},{"issue":"5","key":"10.1016\/j.chc.2022.03.005_bib18","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/archdischild-2019-316928","article-title":"NICE guideline review: attention deficit hyperactivity disorder: diagnosis and management (NG87)","volume":"105","author":"Dalrymple","year":"2020","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"4","key":"10.1016\/j.chc.2022.03.005_bib19","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1212\/WNL.58.4.527","article-title":"Treatment of ADHD in children with tics: a randomized controlled trial","volume":"58","year":"2002","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib20","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/chi.0b013e31815d9af7","article-title":"Clonidine for attention-deficit\/hyperactivity disorder: I. Efficacy and tolerability outcomes","volume":"47","author":"Palumbo","year":"2008","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib21","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jaac.2010.11.005","article-title":"Clonidine extended-release tablets for pediatric patients with attention-deficit\/hyperactivity disorder","volume":"50","author":"Jain","year":"2011","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib22","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1542\/peds.2006-3695","article-title":"A\u00a0randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder","volume":"121","author":"Biederman","year":"2008","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/CHI.0b013e318191769e","article-title":"Guanfacine extended release in children and adolescents with attention-deficit\/hyperactivity disorder: a placebo-controlled trial","volume":"48","author":"Sallee","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11","key":"10.1016\/j.chc.2022.03.005_bib24","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.jaac.2015.08.016","article-title":"A\u00a0randomized, placebo-controlled trial of guanfacine extended release in adolescents with attention-deficit\/hyperactivity disorder","volume":"54","author":"Wilens","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2022.03.005_bib25","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1007\/s40263-019-00683-7","article-title":"Clinically significant drug-drug interactions with agents for attention-deficit\/hyperactivity disorder","volume":"33","author":"Schoretsanitis","year":"2019","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1186\/s12888-020-02867-8","article-title":"Safety and efficacy of guanfacine extended-release in adults with attention-deficit\/hyperactivity disorder: an open-label, long-term, phase 3 extension study","volume":"20","author":"Iwanami","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2022.03.005_bib27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/jcpp.12492","article-title":"Extended-release guanfacine hydrochloride in 6-17-year olds with ADHD: a randomised-withdrawal maintenance of efficacy study","volume":"57","author":"Newcorn","year":"2016","journal-title":"J\u00a0Child Psychol Psychiatry"},{"issue":"12","key":"10.1016\/j.chc.2022.03.005_bib28","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40263-013-0104-8","article-title":"Efficacy and safety of lisdexamfetaminedimesylate and atomoxetine in the treatment of attention-deficit\/hyperactivity disorder: a head-to-head, randomized, double-blind, phase IIIb study","volume":"27","author":"Dittman","year":"2013","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.chc.2022.03.005_bib29","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaac.2016.05.015","article-title":"Combined Stimulant and Guanfacineadministration in attention-deficit\/hyperactivity disorder: a controlled, comparative study","volume":"55","author":"McCracken","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"6","key":"10.1016\/j.chc.2022.03.005_bib30","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s40263-021-00825-w","article-title":"Viloxazine in the management of CNS disorders: a historical overview and current status","volume":"35","author":"Findling","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.chc.2022.03.005_bib31","first-page":"285","article-title":"New insights into the mechanism of action of viloxazine: serotonin and norepinephrine modulating properties","volume":"12","author":"Yu","year":"2020","journal-title":"J\u00a0Exp Pharmacol"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib32","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1087054719836159","article-title":"A\u00a0phase II double-blind, placebo-controlled, efficacy and safety study of SPN-812 (Extended-Release viloxazine) in children with ADHD","volume":"24","author":"Johnson","year":"2020","journal-title":"J\u00a0Atten Disord"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib33","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1017\/S1092852920000310","article-title":"113 phase 3, randomized, double-blind, placebo-controlled study (P303) assessing efficacy and safety of extended-release viloxazine in children with ADHD","volume":"25","author":"Nasser","year":"2020","journal-title":"CNS Spectrums"},{"issue":"8","key":"10.1016\/j.chc.2022.03.005_bib34","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.clinthera.2020.05.021","article-title":"A\u00a0phase III, randomized, placebo-controlled trial to assess the efficacy and safety of once-daily SPN-812 (viloxazine extended-release) in the treatment of attention-deficit\/hyperactivity disorder in school-age children","volume":"42","author":"Nasser","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.chc.2022.03.005_bib35","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.2147\/NDT.S312011","article-title":"The effect of viloxazine extended-release capsules on functional impairments associated with attention-deficit\/hyperactivity disorder (ADHD) in children and adolescents in four phase 3 placebo-controlled trials","volume":"17","author":"Nasser","year":"2021","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.chc.2022.03.005_bib36","doi-asserted-by":"crossref","first-page":"113664","DOI":"10.1016\/j.psychres.2020.113664","article-title":"Early response to SPN-812 (viloxazine extended-release) can predict efficacy outcome in pediatric subjects with ADHD: a machine learning post-hoc analysis of four randomized clinical trials","volume":"296","author":"Faraone","year":"2021","journal-title":"Psychiatry Res"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib37","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40261-020-00992-6","article-title":"Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and methylphenidate in healthy adults","volume":"41","author":"Faison","year":"2021","journal-title":"Clin Drug Invest"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/JCP.0000000000001361","article-title":"Pharmacokinetics of coadministered viloxazine extended-release (SPN-812) and lisdexamfetamine in healthy adults","volume":"41","author":"Faison","year":"2021","journal-title":"J\u00a0Clin Psychopharmacol"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib39","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s13318-021-00729-6","article-title":"Impact of a high-fat meal and sprinkled administration on the bioavailability and pharmacokinetics of viloxazine extended-release capsules (QelbreeTM) in Healthy Adult Subjects","volume":"47","author":"Wang","year":"2021","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"3","key":"10.1016\/j.chc.2022.03.005_bib40","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1089\/cap.2020.0148","volume":"31","author":"Nasser","year":"2021","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"6","key":"10.1016\/j.chc.2022.03.005_bib41","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s40272-021-00470-2","article-title":"Executive function outcome of treatment with viloxazine extended-release capsules in children and adolescents with attention-deficit\/hyperactivity disorder: a post-hoc analysis of four randomized clinical trials","volume":"23","author":"Faraone","year":"2021","journal-title":"Paediatr Drugs"},{"key":"10.1016\/j.chc.2022.03.005_bib42","article-title":"A\u00a0post hoc analysis of the effect of viloxazine extended-release capsules on learning and school problems in children and adolescents with attention-deficit\/hyperactivity disorder","author":"Faraone","year":"2021","journal-title":"Eur Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib43","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00004583-199301000-00028","article-title":"A\u00a0double-blind placebo controlled study of desipramine in the treatment of ADD: III. Lack of impact of comorbidity and family history factors on clinical response","volume":"32","author":"Biederman","year":"1993","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"11 Pt A","key":"10.1016\/j.chc.2022.03.005_bib44","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1016\/j.bbagen.2017.07.022","article-title":"Differentiating physicochemical properties between NDRIs and sNRIs clinically important for the treatment of ADHD","volume":"1861","author":"Wang","year":"2017","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.chc.2022.03.005_bib45","series-title":"Bupropion. StatPearls. Treasure island(FL): StatPearls Publishing. Copyright \u00a9 2021","author":"Huecker","year":"2021"},{"issue":"10","key":"10.1016\/j.chc.2022.03.005_bib46","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1001\/archpsyc.1985.01790330042005","article-title":"Treatment of hyperactive children with monoamine oxidase inhibitors. I. Clinical efficacy","volume":"42","author":"Zametkin","year":"1985","journal-title":"Arch Gen Psychiatry"},{"issue":"10","key":"10.1016\/j.chc.2022.03.005_bib47","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1097\/00004583-199610000-00018","article-title":"Bupropion hydrochloride in attention deficit disorder with hyperactivity","volume":"35","author":"Conners","year":"1996","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"issue":"7","key":"10.1016\/j.chc.2022.03.005_bib48","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.biopsych.2005.01.027","article-title":"Bupropion XL in adults with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled study","volume":"57","author":"Wilens","year":"2005","journal-title":"Biol Psychiatry"},{"issue":"2","key":"10.1016\/j.chc.2022.03.005_bib49","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1007\/s12325-009-0008-7","article-title":"Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review","volume":"26","author":"Verbeeck","year":"2009","journal-title":"Adv Ther"},{"key":"10.1016\/j.chc.2022.03.005_bib50","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jad.2015.03.006","article-title":"Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion","volume":"178","author":"Stuhec","year":"2015","journal-title":"J\u00a0Affect Disord"},{"issue":"10","key":"10.1016\/j.chc.2022.03.005_bib51","first-page":"Cd009504","article-title":"Bupropion for attention deficit hyperactivity disorder (ADHD) in adults","volume":"10","author":"Verbeeck","year":"2017","journal-title":"CochraneDatabase Syst Rev"},{"issue":"5","key":"10.1016\/j.chc.2022.03.005_bib52","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1089\/cap.2005.15.777","article-title":"Bupropion SR for the treatment of substance-abusing outpatient adolescents with attention-deficit\/hyperactivity disorder and mood disorders","volume":"15","author":"Solhkhah","year":"2005","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.chc.2022.03.005_bib53","unstructured":"Atripla\u2014PIhttp:\/\/packageinserts.bms.com\/pi\/pi_atripla.pdf. Foster City (CA): Gilead Sciences Inc. ."},{"issue":"3\u20134","key":"10.1016\/j.chc.2022.03.005_bib54","first-page":"37","article-title":"Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison","volume":"11","author":"Sansone","year":"2014","journal-title":"Innov Clin Neurosci"},{"key":"10.1016\/j.chc.2022.03.005_bib55","doi-asserted-by":"crossref","first-page":"717","DOI":"10.3389\/fpsyt.2020.00717","article-title":"Antidepressants in children and adolescents: meta-review of efficacy, tolerability and suicidality in acute treatment","volume":"11","author":"Boaden","year":"2020","journal-title":"Front Psychiatry"},{"issue":"5","key":"10.1016\/j.chc.2022.03.005_bib56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1097\/00004583-198909000-00022","article-title":"A\u00a0double-blind placebo controlled study of desipramine in the treatment of ADD: I. Efficacy","volume":"28","author":"Biederman","year":"1989","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.chc.2022.03.005_bib57","series-title":"Oxford textbook of attention deficit hyperactivity disorder","first-page":"393","article-title":"Non-Stimulants in the treatment of ADHD","author":"Dittman","year":"2018"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib58","first-page":"55","article-title":"Amantadine: a review of use in child and adolescent psychiatry","volume":"22","author":"Hosenbocus","year":"2013","journal-title":"J\u00a0Can Acad Child Adolesc Psychiatry"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib59","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1089\/cap.2006.0044","article-title":"A\u00a0pilot evaluation of the safety, tolerability, pharmacokinetics, and effectiveness of memantine in pediatric patients with attention-deficit\/hyperactivity disorder combined type","volume":"17","author":"Findling","year":"2007","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2022.03.005_bib60","doi-asserted-by":"crossref","first-page":"291","DOI":"10.3109\/15622975.2011.623716","article-title":"A\u00a0pilot open label prospective study of memantine monotherapy in adults with ADHD","volume":"14","author":"Surman","year":"2013","journal-title":"World J Biol Psychiatry"},{"issue":"7\u20138","key":"10.1016\/j.chc.2022.03.005_bib61","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/hup.1154","article-title":"Amantadine versus methylphenidate in children and adolescents with attention deficit\/hyperactivity disorder: a randomized, double-blind trial","volume":"25","author":"Mohammadi","year":"2010","journal-title":"Hum Psychopharmacol"},{"issue":"4","key":"10.1016\/j.chc.2022.03.005_bib62","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1177\/1087054714538656","article-title":"Memantine in the treatment of executive function deficits in adults with ADHD","volume":"21","author":"Biederman","year":"2017","journal-title":"J\u00a0Atten Disord"},{"issue":"1","key":"10.1016\/j.chc.2022.03.005_bib63","doi-asserted-by":"crossref","first-page":"137","DOI":"10.4088\/JCP.v67n0120","article-title":"Modafinil film-coated tablets in children and adolescents with attention-deficit\/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation","volume":"67","author":"Swanson","year":"2006","journal-title":"J\u00a0Clin Psychiatry"},{"issue":"9","key":"10.1016\/j.chc.2022.03.005_bib64","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S2215-0366(18)30269-4","article-title":"Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis","volume":"5","author":"Cortese","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.chc.2022.03.005_bib65","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.jpsychires.2016.09.034","article-title":"Modafinil for the treatment of attention-deficit\/hyperactivity disorder: a meta-analysis","volume":"84","author":"Wang","year":"2017","journal-title":"J\u00a0Psychiatr Res"},{"issue":"7","key":"10.1016\/j.chc.2022.03.005_bib66","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1080\/14737175.2019.1628640","article-title":"Beyond stimulants: a systematic review of randomised controlled trials assessing novel compounds for ADHD","volume":"19","author":"Nageye","year":"2019","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.chc.2022.03.005_bib67","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.2147\/NDT.S242084","article-title":"Safety and efficacy of centanafadine sustained-release in adults with attention-deficit hyperactivity disorder: results of phase 2 studies","volume":"16","author":"Wigal","year":"2020","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.chc.2022.03.005_bib68","first-page":"2321","article-title":"Pilot Phase II study of mazindol in children with attention deficit\/hyperactivity disorder","volume":"8","author":"Konofal","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"3","key":"10.1016\/j.chc.2022.03.005_bib69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s40263-018-0503-y","article-title":"A\u00a0double-blind, placebo-controlled, phase II study to determine the efficacy, safety, tolerability and pharmacokinetics of a controlled release (CR) formulation of mazindol in adults with DSM-5 attention-deficit\/hyperactivity disorder (ADHD)","volume":"32","author":"Wigal","year":"2018","journal-title":"CNS Drugs"}],"container-title":["Child and Adolescent Psychiatric Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499322000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056499322000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T22:49:24Z","timestamp":1761000564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056499322000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":69,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1056499322000244"],"URL":"https:\/\/doi.org\/10.1016\/j.chc.2022.03.005","relation":{},"ISSN":["1056-4993"],"issn-type":[{"value":"1056-4993","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonstimulant Treatments for ADHD","name":"articletitle","label":"Article Title"},{"value":"Child and Adolescent Psychiatric Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.chc.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}